Related Experiment Videos
Autologous bone marrow purging with LAK cells
L Giuliodori1, L Moretti, S Stramigioli
1Division of Hematology, USSL 3, Pesaro, Italy.
The International Journal of Artificial Organs
|December 1, 1993
Summary
This study shows that lymphokine-activated killer (LAK) cells can effectively target hematologic cancer cells while minimally harming stem cells. This makes LAK cells a promising option for purging bone marrow in transplantation.
Area of Science:
- Immunology
- Hematology
- Oncology
Background:
- Hematologic malignancies pose significant treatment challenges.
- Autologous bone marrow transplantation (BMT) is a key therapeutic strategy.
- Effective purging of residual cancer cells from autologous marrow is crucial.
Purpose of the Study:
- To evaluate the efficacy of lymphokine-activated killer (LAK) cells in lysing hematologic neoplastic cells.
- To assess the toxicity of LAK cells towards autologous stem cells.
- To determine the potential of LAK cells for ex vivo marrow purging in autologous BMT.
Main Methods:
- Co-culture of bone marrow and LAK cells at a 1:1 ratio for 8 hours.
- Assessment of inhibition on granulocyte-erythroid-monocyte-macrophage (GEMM) colony formation.
- Comparison of LAK-treated marrow with untreated marrow.
Main Results:
- LAK cells demonstrated lysis of hematologic neoplastic cells in vitro.
- A minor toxicity was observed on staminal autologous marrow cells.
- Inhibition on GEMM colonies was 20% less in LAK co-cultured marrow compared to untreated marrow.
Conclusions:
- LAK cells exhibit selective cytotoxicity against hematologic cancer cells.
- LAK cells show acceptable toxicity profiles for autologous stem cells.
- LAK cells represent a promising agent for marrow purging in autologous BMT.